Kevin M. Krause, MBA

AN2

Disclosure(s): AN2 Therapeutics: Employee, Stocks/Bonds

Poster(s):

• 593 - Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 619 - Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET